Oral antineoplastic indicated as maintenance treatment for adult patients with acute myeloid leukemia (AML).
Pembrox
Antineoplastic, anti-PD-1 monoclonal antibody. Immunotherapy indicated for various advanced tumors such as non-small cell lung cancer, renal cancer, triple-negative breast cancer, cervical cancer, endometrial cancer, melanoma, among others.
Catiz
Tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic HER2-positive breast cancer, in combination with trastuzumab and capecitabine.
Visedge
Oral antineoplastic, Hedgehog pathway inhibitor indicated for the treatment of adult patients with metastatic and/or locally advanced basal cell carcinoma.
Exobozan
Antineoplastic, tyrosine kinase inhibitor, indicated as an oral treatment for patients with advanced renal cancer or as a second-line treatment for hepatocellular carcinoma.
Ixomida
Hormonal antineoplastic agent Antiandrogen indicated for the treatment of patients with metastatic castration-sensitive prostate cancer or with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of progression.
Reglicat
Antineoplastic. EGFR, tyrosine kinase inhibitor. Indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations.
Dafex
Antineoplastic, anti-HER2 monoclonal antibody indicated for HER2+ breast cancer and advanced gastric cancer.
Gineva
Antineoplastic agent. Indicated as treatment for specific tumors in adults (advanced RH+ breast cancer, renal cancer, subependymal giant cell astrocytoma, advanced neuroendocrine tumors), and to prevent the growth of other noncancerous cells associated with a genetic disorder called tuberous sclerosis (TS) in children or adults.
Perciclib
Antineoplastic cyclin-dependent kinase (CDK) inhibitor indicated for the treatment of patients with hormone receptor positive advanced breast cancer (HR+HER2-).
